Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating)‘s stock had its “reiterates” rating reiterated by 500.com in a research note issued to investors on Wednesday, Benzinga reports. Several other equities research analysts also recently weighed in on the company. B. Riley cut their price target on Arrowhead Pharmaceuticals from $59.00 to $55.00 and set a “buy” rating […]
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) will issue its quarterly earnings data after the market closes on Tuesday, May 2nd. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link. Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get […]
Retirement Systems of Alabama grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 0.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 332,712 shares of the biotechnology company’s stock after acquiring an additional 936 shares during the period. Retirement Systems of […]
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) have received an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price […]
Sumitomo Mitsui Financial Group started coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) in a research report released on Wednesday, Briefing.com reports. The brokerage issued an outperform rating and a $80.00 price target on the biotechnology company’s stock. A number of other equities analysts have also recently commented on the stock. StockNews.com started […]